REPLIGEN CORPRGENEarnings & Financial Report
Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...
RGEN Q1 FY2026 Key Financial Metrics
Revenue
$194.3M
Gross Profit
$108.3M
Operating Profit
$15.9M
Net Profit
$8.3M
Gross Margin
55.7%
Operating Margin
8.2%
Net Margin
4.3%
YoY Growth
14.8%
EPS
$0.15
REPLIGEN CORP Q1 FY2026 Financial Summary
REPLIGEN CORP reported revenue of $194.3M (up 14.8% YoY) for Q1 FY2026, with a net profit of $8.3M (up 42.9% YoY) (4.3% margin). Cost of goods sold was $86.0M, operating expenses totaled $92.3M.
Key Financial Metrics
| Total Revenue | $194.3M |
|---|---|
| Net Profit | $8.3M |
| Gross Margin | 55.7% |
| Operating Margin | 8.2% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
REPLIGEN CORP Q1 FY2026 revenue of $194.3M breaks down across 2 segments, led by Product at $194.2M (100.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Product | $194.2M | 100.0% |
| Royalty and other revenue | $44.0K | 0.0% |
REPLIGEN CORP Annual Revenue by Year
REPLIGEN CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $738.3M).
REPLIGEN CORP Quarterly Revenue & Net Profit History
REPLIGEN CORP results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $194.3M | +14.8% | $8.3M | 4.3% |
| Q4 FY2025 | $197.9M | +13.6% | $13.3M | 6.7% |
| Q3 FY2025 | $188.8M | +21.9% | $14.9M | 7.9% |
| Q2 FY2025 | $182.4M | +18.4% | $14.9M | 8.2% |
| Q1 FY2025 | $169.2M | +11.8% | $5.8M | 3.4% |
| Q4 FY2024 | $174.1M | +11.8% | $-30.3M | -17.4% |
| Q3 FY2024 | $154.9M | +9.7% | $-654.0K | -0.4% |
| Q2 FY2024 | $154.1M | -3.2% | $3.3M | 2.2% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $154.1M | $154.9M | $174.1M | $169.2M | $182.4M | $188.8M | $197.9M | $194.3M |
| YoY Growth | -3.2% | 9.7% | 11.8% | 11.8% | 18.4% | 21.9% | 13.6% | 14.8% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.86B | $2.83B | $2.83B | $2.85B | $2.90B | $2.92B | $2.95B | $2.93B |
| Liabilities | $875.6M | $814.0M | $856.9M | $866.7M | $839.9M | $840.6M | $843.6M | $825.3M |
| Equity | $1.99B | $2.02B | $1.97B | $1.99B | $2.06B | $2.08B | $2.11B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $42.2M | $49.3M | $39.2M | $15.0M | $28.6M | $48.1M | $25.7M |